ClinicalTrials.gg
RecruitingNCT07866859Updated Oct 14, 2026

Common Femoral Vein-to-Artery Diameter Ratio for Detection of Elevated LVEDP

An observational study in Acute Coronary Syndrome, Chronic Coronary Syndrome and Heart Failure, sponsored by Burapha University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Burapha University · Observational

Updated Oct 14, 2026Eligibility revisedNewly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
105
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This prospective cross-sectional diagnostic accuracy study enrolled patients undergoing coronary angiography and left heart catheterization at Burapha University Hospital, Thailand. The diameters of the common femoral vein and common femoral artery were measured using ultrasonography, and the common FVD/FAD ratio was calculated. LVEDP, measured during left heart catheterization, served as the reference standard. An elevated LVEDP (>16 mmHg) was defined as volume overload. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.

Read the detailed description

Diagnostic accuracy study

02

Conditions studied

  • Acute Coronary Syndrome
  • Chronic Coronary Syndrome
  • Heart Failure

Keywords

  • femoral artery, femoral vein, ultrasound, Elevated LVEDP
03

In context

Acute Coronary Syndrome

1,492 studies on the registry are indexed under Acute Coronary Syndrome; 270 are open to participants now.

This study's planned enrollment of 105 is below the median of 500 across 579 observational studies indexed under Acute Coronary Syndrome.

Browse Acute Coronary Syndrome studies →

Lead sponsor

Burapha University is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult patients (aged ≥18 years) who were scheduled to undergo coronary angiography with left heart catheterization

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (aged ≥18 years)
  • Adult patients were scheduled to undergo coronary angiography with left heart catheterization

Exclusion criteria

Exclusion Criteria:

  • Contraindications to cardiac catheterization
  • Inability to obtain accurate ultrasonographic measurements of the common femoral vein or common femoral artery diameters
  • Inability to advance a guidewire across the aortic valve into the left ventricle for measurement of LVEDP.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
105 participants (estimated)
Target follow-up
105 Days
Patient registry
Yes

Groups and cohorts

  • Patients Undergoing Left Heart Catheterization

    Adults undergoing clinically indicated coronary angiography and left heart catheterization were enrolled in this prospective cross-sectional diagnostic accuracy study. All participants underwent ultrasound examination of the common femoral vein and common femoral artery to measure their diameters and calculate the common femoral vein-to-artery diameter ratio. Left ventricular end-diastolic pressure was measured during left heart catheterization as the reference standard. No study intervention was administered.

    Diagnostic Test: Ultrasound Measurement of Common Femoral Vein-to-Artery Diameter Ratio

Interventions

  • Diagnostic testUltrasound Measurement of Common Femoral Vein-to-Artery Diameter Ratio

    Ultrasound measurement of the common femoral vein and common femoral artery diameters performed in the supine position. The common femoral vein-to-artery diameter ratio is calculated from the measured vessel diameters and evaluated as a diagnostic index for detecting elevated left ventricular end-diastolic pressure. The ultrasound examination is non-invasive and does not involve administration of any therapeutic intervention.

06

What researchers measure

Primary outcomes

  1. Left ventricular end diastolic pressure

    Left ventricular end diastolic pressure measured by left heart catheterization

    Time frame: During the cardiac catheterization procedure

07

Study locations

1 of 1 sites recruiting
  • Burapha University Hospital
    Chon Buri, 20131, Thailand
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — all IPD collected throughout the trial, only IPD used in the results publication

09

Updates

2 registry updates since Sep 25, 2026
Also revised
eligibility
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Oct 14, 2026
    Eligibility Criteria revised
    + 4 other changes: index terms, identifiers, conditions and references
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866859
Lead sponsor
Burapha University
Responsible party
Sukrisd Koowattanatianchai (Assistant Professor of Medicine, Burapha University) — Principal investigator
First posted
Oct 8, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 14, 2026

Study contacts

Sukrisd Koowattanatianchai, Doctor
Contact
sukrisd.ko@go.buu.ac.th
+66-86633007

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion